Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 7/2019

01-07-2019 | Glucocorticoid | Rheumatoid Arthritis (L Moreland, Section Editor)

Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis

Authors: Giovanni Adami, Kenneth G. Saag

Published in: Current Rheumatology Reports | Issue 7/2019

Login to get access

Abstract

Purpose of Review

To review the burden of osteoporosis (OP) in rheumatoid arthritis (RA) and to describe the OP screening strategies applied in RA.

Recent Findings

RA is an inflammatory condition that predisposes patients to development of OP. OP in RA has a multifactorial pathogenesis with systemic inflammation and glucocorticoid use playing major roles. Newer studies have reported an intriguing association between RA autoantibodies and the development of OP. OP screening strategies in RA patients include clinical and vitamin D assessment, biochemical markers of bone remodeling, and bone imaging evaluations, particularly dual-energy X-ray absorptiometry (DXA).

Summary

Fragility fractures are an important comorbidity of RA. OP screening strategies are both feasible and effective in RA patients and recommended by most specialty organizations. Given the considerable exposure to factors related to OP development, such as pro-inflammatory cytokines and glucocorticoid treatment, special attention should be directed to biochemical and DXA results in RA patients.
Literature
1.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19.PubMed
2.
Zhu TY, Griffith JF, Qin L, Hung VW, Fong T-N, Au S-K, et al. Alterations of bone density, microstructure, and strength of the distal radius in male patients with rheumatoid arthritis: a case-control study with HR-pQCT. J Bone Miner Res Off J Am Soc Bone Miner Res. 2014;29:2118–29.
3.
Stach CM, Bäuerle M, Englbrecht M, Kronke G, Engelke K, Manger B, et al. Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum. 2010;62:330–9.PubMed
4.
Ziegelasch M, Forslind K, Skogh T, Riklund K, Kastbom A, Berglin E. Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year. Arthritis Res Ther. 2017;19:195.PubMedPubMedCentral
5.
Nieuwenhuis WP, van Steenbergen HW, Stomp W, Stijnen T, Huizinga TWJ, Bloem JL, et al. The course of bone marrow edema in early undifferentiated arthritis and rheumatoid arthritis: a longitudinal magnetic resonance imaging study at bone level. Arthritis Rheumatol Hoboken NJ. 2016;68:1080–8.
6.
Black RJ, Spargo L, Schultz C, Chatterton B, Cleland L, Lester S, et al. Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritis. Arthritis Care Res. 2014;66:515–22.
7.
Mangnus L, van Steenbergen HW, Reijnierse M, Kälvesten J, van der Helm-Van Mil A. Bone mineral density loss in clinically suspect arthralgia is associated with subclinical inflammation and progression to clinical arthritis. Scand J Rheumatol. 2017;46:364–8.PubMed
8.
Kato G, Shimizu Y, Arai Y, Suzuki N, Sugamori Y, Maeda M, et al. The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. Arthritis Res Ther. 2015;17:251.PubMedPubMedCentral
9.
Fessler J, Husic R, Schwetz V, Lerchbaum E, Aberer F, Fasching P, et al. Senescent T-cells promote bone loss in rheumatoid arthritis. Front Immunol. 2018;9:95.PubMedPubMedCentral
10.
Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis. 2015;74:2151–6.PubMed
11.
Engdahl C, Bang H, Dietel K, Lang SC, Harre U, Schett G. Periarticular bone loss in arthritis is induced by autoantibodies against citrullinated vimentin. J Bone Miner Res Off J Am Soc Bone Miner Res. 2017;32:1681–91.
12.
Simon D, Kleyer A, Englbrecht M, Stemmler F, Simon C, Berlin A, et al. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin. Bone. 2018;116:87–93.PubMed
13.
Behrens F, Koehm M, Thaçi D, Gnann H, Greger G, Maria Wittig B, et al. Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. Rheumatol Oxf Engl. 2016;55:1791–5.
14.
Kocijan R, Harre U, Schett G. ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep. 2013;15:366.PubMed
15.
Krishnamurthy A, Joshua V, Haj Hensvold A, Jin T, Sun M, Vivar N, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75:721–9.PubMed
16.
•• Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73:854–60. This article provides evidence on the independent activity of ACPA on bone health. The authors found that bone loss ACPA-positive patients experience bone loss even before the onset of clinical RA.PubMed
17.
Haugeberg G, Helgetveit KB, Førre Ø, Garen T, Sommerseth H, Prøven A. Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord. 2014;15:289.PubMedPubMedCentral
18.
Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol. 2012;8:684–9.PubMed
19.
Hauser B, Riches PL, Gilchrist T, Visconti MR, Wilson JF, Ralston SH. Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1631–2.PubMed
20.
•• Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–63. This important pre-clinical paper provides evidence on the crucial role of Dkk-1 in bone loss and bone erosions.PubMed
21.
Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol. 2015;33:77–83.PubMed
22.
Ma Y, Zhang X, Wang M, Xia Q, Yang J, Wu M, et al. The serum level of Dickkopf-1 in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int Immunopharmacol. 2018;59:227–32.PubMed
23.
Orsolini G, Caimmi C, Viapiana O, Idolazzi L, Fracassi E, Gatti D, et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int. 2017;101:17–23.PubMed
24.
Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM, et al. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos. 2018;13:30.PubMedPubMedCentral
25.
Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2016;27:1709–18.
26.
Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR. Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions. J Bone Miner Res Off J Am Soc Bone Miner Res. 2018;33:1881–8.
27.
• Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O’Malley CD, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2016;27:3239–49. This is a cross-sectional study on fracture risk associated with glucocorticoid use in RA patients. The authors found an increased risk of fracture among young and newly diagnosed RA patients. The fracture risk was directly related to daily and cumulative dose of glucocorticoids.
28.
Da Silva JAP, Jacobs JWG, Kirwan JR, Boers M, Saag KG, Inês LBS, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.PubMed
29.
Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S, Champion GD. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis. 1986;45:950–3.PubMedPubMedCentral
30.
Blavnsfeldt A-BG, de Thurah A, Thomsen MD, Tarp S, Langdahl B, Hauge E-M. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials. Bone. 2018;114:172–80.PubMed
31.
Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V, et al. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res. 2015;67:754–64.
32.
van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12.PubMed
33.
Emkey RD, Lindsay R, Lyssy J, Weisberg JS, Dempster DW, Shen V. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:277–82.PubMed
34.
Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54:49–52.PubMedPubMedCentral
35.
Simon D, Kleyer A, Stemmler F, Simon C, Berlin A, Hueber AJ, et al. Age- and sex-dependent changes of intra-articular cortical and trabecular bone structure and the effects of rheumatoid arthritis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2017;32:722–30.
36.
Rossini M, Adami G, Viapiana O, Idolazzi L, Orsolini G, Fassio A, et al. Osteoporosis: an independent determinant of bone erosions in rheumatoid arthritis? J Bone Miner Res Off J Am Soc Bone Miner Res. 2017;32:2142–3.
37.
Han MH, Ryu JI, Kim CH, Kim JM, Cheong JH, Bak KH, et al. Influence of systemic bone mineral density on atlantoaxial subluxation in patients with rheumatoid arthritis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2017;28:1931–8.
38.
Wilson JC, Sarsour K, Gale S, Pethö-Schramm A, Jick SS, Meier CR. Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis. Arthritis Care Res. 2019;71:498–511.
39.
Mori Y, Kuwahara Y, Chiba S, Kogre A, Baba K, Kamimura M, et al. Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment. J Bone Miner Metab. 2017;35:52–7.PubMed
40.
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43:522–30.PubMed
41.
Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000;27:2582–9.PubMed
42.
Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatol Oxf Engl. 2014;53:1759–66.
43.
Lee J-H, Sung Y-K, Choi C-B, Cho S-K, Bang S-Y, Choe J-Y, et al. The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:98.PubMedPubMedCentral
44.
Fassio A, Idolazzi L, Jaber MA, Dartizio C, Viapiana O, Rossini M, et al. The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo. 2016;68:65–71.PubMed
45.
Kweon S-M, Sohn DH, Park J-H, Koh JH, Park E-K, Lee H-N, et al. Male patients with rheumatoid arthritis have an increased risk of osteoporosis: frequency and risk factors. Medicine (Baltimore). 2018;97:e11122.
46.
Jin S, Hsieh E, Peng L, Yu C, Wang Y, Wu C, et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2018;29:1263–75.
47.
Mazzucchelli R, Pérez Fernandez E, Crespí-Villarías N, Quirós-Donate J, García Vadillo A, Espinosa M, et al. Trends in hip fracture in patients with rheumatoid arthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999-2015). TREND-AR study. RMD Open. 2018;4:e000671.PubMedPubMedCentral
48.
Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, et al. Choosing wisely: the American College of Rheumatology’s top 5 list of things physicians and patients should question. Arthritis Care Res. 2013;65:329–39.
49.
Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73:62–8.PubMed
50.
Venegas-Pont M, Davis JM, Crowson CS, Gabriel SE, Matteson EL. Frequency of radiologic procedures in patients with rheumatoid arthritis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2015;21:15–8.
51.
Ozen G, Kamen DL, Mikuls TR, England BR, Wolfe F, Michaud K. Trends and determinants of osteoporosis treatment and screening in patients with rheumatoid arthritis compared to osteoarthritis. Arthritis Care Res. 2018;70:713–23.
52.
Amarnath ALD, Franks P, Robbins JA, Xing G, Fenton JJ. Underuse and overuse of osteoporosis screening in a regional health system: a retrospective cohort study. J Gen Intern Med. 2015;30:1733–40.PubMedPubMedCentral
53.
Schmajuk G, Tonner C, Trupin L, Yazdany J. Variations in radiographic procedure use for Medicare patients with rheumatoid arthritis. Arthritis Care Res. 2017;69:642–8.
54.
Lewiecki EM, Baim S, Siris ES. Osteoporosis care at risk in the United States. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2008;19:1505–9.
55.
Richards JS, Cannon GW, Hayden CL, Amdur RL, Lazaro D, Mikuls TR, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res. 2012;64:1864–70.
56.
Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the women’s health initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res. 2006;21:765–71.PubMed
57.
Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57:423–8.PubMed
58.
Baillet A, Gossec L, Carmona L, de Wit M, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016;75:965–73.PubMed
59.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol Hoboken NJ. 2017;69:1521–37.
60.
Dougados M, Soubrier M, Perrodeau E, Gossec L, Fayet F, Gilson M, et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann Rheum Dis. 2015;74:1725–33.PubMed
61.
Daïen CI, Tubery A, Beurai-Weber M, du Cailar G, Picot M-C, Jaussent A, et al. Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86:49–54.PubMed
62.
Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2005;16:229–38.
63.
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2008;19:385–97.
64.
Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D, et al. Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD cohort. J Bone Miner Res Off J Am Soc Bone Miner Res. 2017;32:1568–74.
65.
Martineau P, Leslie WD, Johansson H, Harvey NC, McCloskey EV, Hans D, et al. In which patients does lumbar spine trabecular bone score (TBS) have the largest effect? Bone. 2018;113:161–8.PubMedPubMedCentral
66.
Kim D, Cho S-K, Kim JY, Choi YY, Sung Y-K. Association between trabecular bone score and risk factors for fractures in Korean female patients with rheumatoid arthritis. Mod Rheumatol. 2016;26:540–5.PubMed
67.
Choi YJ, Chung Y-S, Suh C-H, Jung J-Y, Kim H-A. Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis. Medicine (Baltimore). 2017;96:e8661.
68.
Deodhar AA, Brabyn J, Jones PW, Davis MJ, Woolf AD. Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis. Ann Rheum Dis. 1994;53:685–90.PubMedPubMedCentral
69.
Alenfeld FE, Diessel E, Brezger M, Sieper J, Felsenberg D, Braun J. Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2000;11:400–7.
70.
Ardicoglu O, Ozgocmen S, Kamanli A, Pekkutucu I. Relationship between bone mineral density and radiologic scores of hands in rheumatoid arthritis. J Clin Densitom Off J Int Soc Clin Densitom. 2001;4:263–9.
71.
Wevers-de Boer KVC, Heimans L, Visser K, Kälvesten J, Goekoop RJ, van Oosterhout M, et al. Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study. Ann Rheum Dis. 2015;74:341–6.PubMed
72.
Hoff M, Haugeberg G, Odegård S, Syversen S, Landewé R, van der Heijde D, et al. Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis. 2009;68:324–9.PubMed
73.
Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, et al. Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis. 2006;65:736–40.PubMed
74.
Klop C, de Vries F, Bijlsma JWJ, Leufkens HGM, Welsing PMJ. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Ann Rheum Dis. 2016;75:2095–100.PubMedPubMedCentral
75.
Cheng T-T, Yu S-F, Su F-M, Chen Y-C, Su BY-J, Chiu W-C, et al. Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture. Arthritis Res Ther. 2018;20:16.PubMedPubMedCentral
76.
Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016;18:226.PubMedPubMedCentral
77.
Lee YH, Bae S-C. Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clin Exp Rheumatol. 2016;34:827–33.PubMed
78.
Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016;27:367–76.PubMed
79.
Brance ML, Brun LR, Lioi S, Sánchez A, Abdala M, Oliveri B. Vitamin D levels and bone mass in rheumatoid arthritis. Rheumatol Int. 2015;35:499–505.PubMed
80.
Hong Q, Xu J, Xu S, Lian L, Zhang M, Ding C. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatol Oxf Engl. 2014;53:1994–2001.
81.
Lin J, Liu J, Davies ML, Chen W. Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One. 2016;11:e0146351.PubMedPubMedCentral
82.
Adami G, Rossini M, Bogliolo L, Cantatore FP, Varenna M, Malavolta N, et al. An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. Mod Rheumatol. 2018;0:1–8.
83.
Soubrier M, Lambert C, Combe B, Gaudin P, Thomas T, Sibilia J, et al. A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2018;36:1056–60.PubMed
84.
Coiffier G, Bouvard B, Chopin F, Biver E, Funck-Brentano T, Garnero P, et al. Common bone turnover markers in rheumatoid arthritis and ankylosing spondylitis: a literature review. Joint Bone Spine. 2013;80:250–7.PubMed
85.
Krabben A, Knevel R, Huizinga TWJ, Cavet G, van der Helm-van Mil AH. Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis. J Rheumatol. 2013;40:1303–6.PubMed
86.
Garnero P, Landewé R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum. 2002;46:2847–56.PubMed
87.
Loddenkemper K, Bohl N, Perka C, Burmester G-R, Buttgereit F. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. Rheumatol Int. 2006;26:331–6.PubMed
88.
Nonaka T, Nishisaka F, Fukuda K, Sohen S, Hamanishi C. Relationship between bone mineral density and urine level of NTx in rheumatoid arthritis. J Bone Miner Metab. 2005;23:314–7.PubMed
89.
Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol. 2000;18:683–90.PubMed
90.
Adami G, Orsolini G, Adami S, Viapiana O, Idolazzi L, Gatti D, et al. Effects of TNF inhibitors on parathyroid hormone and Wnt signaling antagonists in rheumatoid arthritis. Calcif Tissue Int. 2016;99:360–4.PubMed
91.
92.
Fardellone P, Séjourné A, Paccou J, Goëb V. Bone remodelling markers in rheumatoid arthritis. Mediat Inflamm. 2014;2014:484280.
93.
Orsolini G, Adami G, Adami S, Viapiana O, Idolazzi L, Gatti D, et al. Short-term effects of TNF inhibitors on bone turnover markers and bone mineral density in rheumatoid arthritis. Calcif Tissue Int. 2016;98:580–5.PubMed
94.
Cheung AM, Adachi JD, Hanley DA, Kendler DL, Davison KS, Josse R, et al. High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. Curr Osteoporos Rep. 2013;11:136–46.PubMedPubMedCentral
95.
Fouque-Aubert A, Boutroy S, Marotte H, Vilayphiou N, Bacchetta J, Miossec P, et al. Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Ann Rheum Dis. 2010;69:1671–6.PubMed
96.
Barnabe C, Toepfer D, Marotte H, Hauge E-M, Scharmga A, Kocijan R, et al. Definition for rheumatoid arthritis erosions imaged with high resolution peripheral quantitative computed tomography and interreader reliability for detection and measurement. J Rheumatol. 2016;43:1935–40.PubMed
97.
Stemmler F, Simon D, Liphardt A-M, Englbrecht M, Rech J, Hueber AJ, et al. Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures. Ann Rheum Dis. 2018;77:973–80.PubMedPubMedCentral
Metadata
Title
Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis
Authors
Giovanni Adami
Kenneth G. Saag
Publication date
01-07-2019
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 7/2019
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-019-0836-7

Other articles of this Issue 7/2019

Current Rheumatology Reports 7/2019 Go to the issue

Vasculitis (L Espinoza, Section Editor)

Treatment Strategies in ANCA-Associated Vasculitis

Spondyloarthritis (M Khan, Section Editor)

Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis

Chronic Pain (R Staud, Section Editor)

Emotional Awareness and Expression Therapy for Chronic Pain: Rationale, Principles and Techniques, Evidence, and Critical Review

Spondyloarthritis (M Khan, Section Editor)

ILC3 in Axial Spondyloarthritis: the Gut Angle

Correction

Correction to: Cell Senescence in Lupus

Infection and Arthritis (Kevin Winthrop, Section Editor)

In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits